---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Effects of other drugs"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Effects of other drugs. Topics: OptimUM-01 drug interaction cocktail substudy: CYP3A4/5 and P-gp inhibitors and CYP3A4/5 inducers prohibited before dosing, Crizotinib label: strong and moderate CYP3A inhibitors and grapefruit, Crizotinib label: strong CYP3A inducers, and Crizotinib label: gastric acid reducing agents and P-glycoprotein. 4 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Darovasertib

<a id="topic-2.1.2.9.1-1"></a>

### OptimUM-01 drug interaction cocktail substudy: CYP3A4/5 and P-gp inhibitors and CYP3A4/5 inducers prohibited before dosing

> “Moderate and strong inhibitors of CYP2A4/5 or P-gp are prohibited within 7 days, or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.”
> “Intake of strong or moderate inducers of CYP3A4/5, CYP2B6, CYP2C9, CYP2C19, or OAT3 is prohibited during 15 days, or 5 half-lives, whichever is longer, prior to Cycle 1 Day -1.”
> “Intake of vitamin supplements containing Vitamin B6 (pyridoxine), grapefruit/grapefruit juice, or Seville orange juice within 7 days prior to Cycle 1 Day -1.”

Source: [ClinicalTrials.gov NCT03947385](https://clinicaltrials.gov/study/NCT03947385)

<a id="topic-2.1.2.9.1-2"></a>

### Clinical drug interaction studies with darovasertib as the affected drug

No evidence found.

<a id="topic-2.1.2.9.1-3"></a>

### Crizotinib label: strong and moderate CYP3A inhibitors and grapefruit

> “Concomitant use of crizotinib with strong CYP3A inhibitors increases crizotinib plasma concentrations”
> “Avoid concomitant use of strong CYP3A inhibitors.”
> “Avoid grapefruit or grapefruit juice”
> “Use caution with concomitant use of moderate CYP3A inhibitors.”
> “If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the dose of XALKORI to the second dose reduction shown in Table 4 for adult patients with NSCLC or IMT”
> “After discontinuation of a strong CYP3A inhibitor, resume the XALKORI dose used prior to initiating the strong CYP3A inhibitor.”
> “Coadministration of a single 150 mg oral dose of crizotinib with ketoconazole, a strong CYP3A inhibitor, increased crizotinib AUC0-INF by 216% and Cmax by 44% compared to crizotinib alone.”
> “Coadministration of XALKORI 250 mg orally once daily with itraconazole, a strong CYP3A inhibitor, increased crizotinib steady-state AUC by 57% and Cmax by 33% compared to crizotinib alone”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.1-4"></a>

### Crizotinib label: strong CYP3A inducers

> “Concomitant use of crizotinib with strong CYP3A inducers decreases crizotinib plasma concentrations”
> “Avoid concomitant use of strong CYP3A inducers.”
> “Coadministration of XALKORI 250 mg orally twice daily with rifampin, a strong CYP3A inducer, decreased crizotinib steady-state AUC0-Tau by 84% and Cmax by 79%, compared to crizotinib alone”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.9.1-5"></a>

### Crizotinib label: gastric acid reducing agents and P-glycoprotein

> “Gastric Acid Reducing Agents: No clinically significant differences in crizotinib pharmacokinetics were observed when used concomitantly with esomeprazole, a proton pump inhibitor.”
> “Crizotinib is a substrate for P-glycoprotein (P-gp) in vitro.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
